
    
      All subjects are required to meet eligibility requirements and undergo a calcipotriene run-in
      period (Part A) prior to qualifying and randomizing into the study to receive either SNA-120
      or Placebo ointment in combination with calcipotriene ointment (Part B). Combination therapy
      (SNA-120 ointment + calcipotriene ointment or Placebo ointment + calcipotriene ointment) is
      to continue over an 8 week period to evaluate safety, tolerability and the efficacy of
      treatment on both persistent pruritus and the visible signs and symptoms of psoriasis.
    
  